PainChek Ltd

As of June 30, 2024, PainChek Ltd carries a market capitalization of 44.17M, placing it among publicly traded companies globally. Its enterprise value stands at 40.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PainChek Ltd's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2024, PainChek Ltd has 166.13M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 14.78, and the price-to-book ratio stands at 34.23.

These figures are as of June 30, 2024. The EV/Sales ratio of 15.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 40.61M versus a market cap of 44.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, PainChek Ltd maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, PainChek Ltd posted a negative return on equity (ROE) of -848.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -238.14, reflecting losses generated across the asset base.

As of the close on October 22, 2026, PainChek Ltd's stock has declined approximately 82.75% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.15.

Over the twelve months ended June 30, 2024, PainChek Ltd generated 2.67M in revenue and converted that into -8.31M in net income, yielding earnings per share of -0.06. EBITDA reached -9.52M, while operating income came in at -9.55M.

These figures are as of June 30, 2024. Total book value stands at 1.29M, with working capital of 1.26M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, PainChek Ltd posted a gross margin of 27.01, reflecting its pricing power and cost economics. The operating margin of -358.19 and net profit margin of -311.72 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -18.59, meaning PainChek Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

PainChek Ltd's most recent stock split took place on December 9, 2025 with a 10:1 split ratio.

As of June 30, 2024, PainChek Ltd has an Altman Z-Score of -16.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.